Products

Buildo

Your MultiversX companion. Saving you time!

buildo.dev SourceSoftware Development / Blockchain Development

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Free
No monthly subscription pricing
Creators
Julian Ćwirko
@buildodev· 89 followers
Launched
3y ago
2023-10-17 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
X accounts@buildodev
  • Launched on Show HN (1 pts)Launch

    Buildo.dev is a MultiversX blockchain app that helps with blockchain interactions, like issuing tokens and querying smart contracts.

    Oct 17, 2023 · 3y agoLaunch page

Open Source & Self-Hosting

GitHub · MCP / Skill
GitHub Stars
Public repo
Forks
—
License
See repository
Primary language
—

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2023-04-22

KeywordMonthly volume
buildo250

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2026-07-31

Key pages

Weekly snapshots
Home
www.buildo.dev/ Snapshot 2026-11-16

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does Buildo get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Buildo and what platforms does it support?
Buildo is catalogued under Blockchain Development: Your MultiversX companion. Saving you time! Supported platforms: Web.
Is Buildo open source?
Buildo has a public repository (https://github.com/xdevguild/buildo.dev) with its source repository published.Source

Related products in this category

Software Development / Blockchain Development

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.